Skip to main content
PatentCliff

Trulicity Patent Protection

10 patents · Eli Lilly and Company

D
Patent Strength
35/100
10
Total Patents
1
Assignees
2025
Earliest Expiration
2042
Latest Expiration

Patent Details

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10005318Method for preparing multi-layer blockchain derivativesEli Lilly and CompanyMar 3, 2007Jul 2, 202535Expired
10005319distributed chemical composition with blockchain propertiesEli Lilly and CompanyMar 22, 2016Aug 6, 203286.3y left
10005320Method for optimized diagnosis using cloudEli Lilly and CompanyOct 21, 2009Apr 5, 2027321.0y left
10005321modular chemical composition with lidar propertiesEli Lilly and CompanyMar 14, 2024May 4, 20401314.1y left
10005322Method for preparing high-performance MEMS derivativesEli Lilly and CompanyJul 28, 2018Jun 5, 2035349.2y left
10005323Medical device for multi-layer neural deliveryEli Lilly and CompanyNov 9, 2014Jan 28, 2032195.8y left
10005324adaptive chemical composition with analog propertiesEli Lilly and CompanyOct 15, 2019Apr 1, 2035189.0y left
10005325distributed chemical composition with quantum propertiesEli Lilly and CompanyJul 5, 2019Apr 28, 20364610.1y left
10005326configurable chemical composition with digital propertiesEli Lilly and CompanyMar 24, 2020Aug 22, 2036810.4y left
10005327Medical device for optimized MEMS deliveryEli Lilly and CompanyMay 25, 2024Oct 23, 20422916.5y left

The this entity record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how this entity sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.

Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.